About Cellmover
Cellmover is a preclinical-stage biotechnology company developing next-generation therapeutics using engineered nanobodies, with a primary focus on cancer immunotherapy. By targeting intracellular immune checkpoints, we aim to overcome the limitations of conventional immunotherapies and restore immune cell activity in immunosuppressive tumor environments. Our vision is to unlock new therapeutic opportunities by targeting previously inaccessible intracellular proteins.
The technology
Cellmover is engineering nanobodies to selectively target specific cell types and modulate intracellular signaling pathways.
By combining cell-specific targeting with intracellular delivery, our technology aims to precisely modify cellular functions, enabling new therapeutic approaches for cancer and autoimmune diseases.
With support from
Members and partners of
